A review on CXCR4/CXCL12 axis in oncology: no place to hide UM Domanska, RC Kruizinga, WB Nagengast, H Timmer-Bosscha, ... European journal of cancer 49 (1), 219-230, 2013 | 708 | 2013 |
CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy UM Domanska, H Timmer-Bosscha, WB Nagengast, THO Munnink, ... Neoplasia 14 (8), 709-718, 2012 | 224 | 2012 |
Role of chemokines and their receptors in cancer RC Kruizinga, J Bestebroer, P Berghuis, CJC de Haas, TP Links, ... Current pharmaceutical design 15 (29), 3396-3416, 2009 | 89 | 2009 |
Pregnancy-related hemangioblastoma progression and complications in von Hippel-Lindau disease C Frantzen, RC Kruizinga, SJ Van Asselt, BA Zonnenberg, JWM Lenders, ... Neurology 79 (8), 793-796, 2012 | 65 | 2012 |
Calculating optimal surveillance for detection of von Hippel–Lindau-related manifestations RC Kruizinga, WJ Sluiter, EGE de Vries, BA Zonnenberg, CJ Lips, ... Endocrine-Related Cancer 21 (1), 63-71, 2014 | 56 | 2014 |
The chemokine network, a newly discovered target in high grade gliomas UM Domanska, RC Kruizinga, WFA den Dunnen, H Timmer-Bosscha, ... Critical reviews in oncology/hematology 79 (2), 154-163, 2011 | 48 | 2011 |
Staphylococcal SSL5 binding to human leukemia cells inhibits cell adhesion to endothelial cells and platelets. HCJ Walenkamp AM, Bestebroer J, Boer IG, Kruizinga R, Verheul HM, van Strijp JA Cell Oncol, 1-10, 2010 | 36* | 2010 |
The incidence of consecutive manifestations in Von Hippel-Lindau disease ANA van der Horst-Schrivers, WJ Sluiter, RC Kruizinga, ... Familial Cancer 18, 369-376, 2019 | 19 | 2019 |
Vascular Endothelial Growth Factor A isoform mRNA expression in pediatric acute myeloid leukemia RC Kruizinga, HJM de Jonge, KR Kampen, AME Walenkamp, E de Bont Pediatric blood & cancer 56 (2), 294-297, 2011 | 14 | 2011 |
Difference in CXCR4 expression between sporadic and VHL-related hemangioblastoma RC Kruizinga, DMS van Marion, WFA den Dunnen, JC de Groot, ... Familial cancer 15, 607-616, 2016 | 13 | 2016 |
Pregnancy and von Hippel-Lindau disease C Frantzen, SJ van Asselt, RC Kruizinga, C Abadie, I Coupier, S Richard, ... Journal of Neurosurgery 118 (6), 1380-1382, 2013 | 4 | 2013 |
The incidence of consecutive manifestations of VHL disease C Frantzen, RC Kruizinga, WJ Sluiter, BA Zonnenberg, CJ Lips, ... Endocrine Abstracts 37, 2015 | | 2015 |
CXCR4 expression in VHL-related and sporadic hemangioblastomas. RC Kruizinga, WFA den Dunnen, EGE de Vries, TP Links, ... Cancer Research 73 (8_Supplement), 93-93, 2013 | | 2013 |
Role of VEGFA, CXCR4 and VHL mutation in tumour behaviour RC Kruizinga | | 2013 |
Mitochondrial and bacterial peptides act on the formyl peptide receptor (FPR) to promote migration and proliferation in high grade glioblastoma cells JC Boer, UM Domanska, RC Kruizinga, I Boer, CJC de Haas, EG de Vries, ... Cancer Research 71 (8_Supplement), 1672-1672, 2011 | | 2011 |
CXCR4 inhibition sensitizes prostate cancer cells to conventional chemotherapy in an in vitro co-culture model UM Domanska, RC Kruizinga, WB Nagengast, HT Bosscha, EGE de Vries, ... Cancer Research 71 (8_Supplement), 522-522, 2011 | | 2011 |
P51. Pregnancy stimulates cerebellar hemangioblastoma growth in von Hippel-Lindau disease C Frantzen, RC Kruizinga, SJ van Asselt, BA Zonnenberg, JWM Lenders, ... | | 2011 |
Sunitinib treatment induces up-regulation of CXCR4 U Kubacka, WB Nagengast, RC Kruizinga, MN Lub-deHooge, JA Gietema, ... Cancer Research 70 (8_Supplement), 380-380, 2010 | | 2010 |
Pregnancy-related hemangioblastoma progression and C Frantzen, RC Kruizinga, SJ van Asselt | | |